KYMR supply chain intelligence for Kymera Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Kymera Therapeutics, Inc. (KYMR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SNYNF | Sanofi | 90% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from SNYN… |
| CCCC | C4 Therapeutics, Inc. | 72% | hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there a… |
| CCCC | C4 Therapeutics, Inc. | 72% | Reciprocal relationship from CCCC graph: Reciprocal relationship from KYMR graph: hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of th… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from GILD g… |
| GILD | Gilead Sciences, Inc. | 72% | hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there a… |
| GLUE | Monte Rosa Therapeutics, Inc. | 72% | Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t… |
| JNJ | Johnson & Johnson | 72% | hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there a… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from KYMR graph: hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of the… |
| NRIX | Nurix Therapeutics, Inc. | 72% | hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there a… |
| NRIX | Nurix Therapeutics, Inc. | 72% | Reciprocal relationship from NRIX graph: Reciprocal relationship from KYMR graph: hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of th… |
| SNYNF | Sanofi | 72% | ch on the targets, and Vertex was responsible for development, manufacturing, and commercialization of the product candidates after it exercises its option to license. The initial research term of th… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SANOFI | SANOFI | 92% | Under the Sanofi Agreement, we granted to Sanofi a worldwide exclusive license to develop, manufacture and commercialize certain lead compounds generated during the collaboration |
| SNYNF | Sanofi | 92% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from SNYN… |
| GENZYME-CORPORATION | GENZYME-CORPORATION | 90% | On July 7, 2020, we entered into a collaboration agreement, or the Original Sanofi Agreement, with Genzyme Corporation, a subsidiary of Sanofi, to co-develop drug candidates directed to two biologica… |
| CCCC | C4 Therapeutics, Inc. | 72% | Reciprocal relationship from CCCC graph: Reciprocal relationship from KYMR graph: current or future product candidates over current treatment options or alternative treatments, including future alter… |
| CCCC | C4 Therapeutics, Inc. | 72% | current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t… |
| GILD | Gilead Sciences, Inc. | 72% | nties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able … |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from KYMR graph: nties associated with product development, we are unable to predict the timing or amount of increased expenses or whe… |
| GLUE | Monte Rosa Therapeutics, Inc. | 72% | Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from KYMR graph: current or future product candidates over current treatment options or alternative treatments, including future altern… |
| JNJ | Johnson & Johnson | 72% | current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t… |
| NRIX | Nurix Therapeutics, Inc. | 72% | Reciprocal relationship from NRIX graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from NRIX g… |
| NRIX | Nurix Therapeutics, Inc. | 72% | current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t… |
| NVSEF | Novartis AG | 72% | ons by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would we… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KYMR graph: ons by the U.S. Congress, the U.S… |
| SNYNF | Sanofi | 72% | ch on the targets, and Vertex was responsible for development, manufacturing, and commercialization of the product candidates after it exercises its option to license. The initial research term of th… |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | ess overall. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to … |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | Reciprocal relationship from VRTX graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from KYMR graph: ess overall. Because of the numerou… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| KYMR-DEBT | Debt stack $80.5M | 90% | Market cache reports total debt of $80.5M. |
| KYMR-DEBT-10596 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| KYMR-OWNER-AVORO-CAPITAL-ADVISORS-LLC | Avoro Capital Advisors LLC | 90% | 13F overlay lists Avoro Capital Advisors LLC as top holder; 262 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 |